Contrast-enhanced US of High-Risk Indeterminate Focal Liver Observations Categorized as LR-4 or LR-M at CT/MRI.

Abstract:

Background Indeterminate focal liver observations in patients at risk for hepatocellular carcinoma (HCC) may require invasive biopsy or follow-up, which could lead to delays in definitive categorization and to postponement of treatment. Purpose To examine clinical effect of contrast-enhanced US (CEUS) in participants with high-risk indeterminate liver observations categorized as Liver Imaging Reporting and Data System (LI-RADS) category LR-4 (probably HCC) or LI-RADS category LR-M (probably or definitely malignant but not HCC specific) at CT or MRI. Materials and Methods This was a secondary analysis of a prospective international multicenter validation study for CEUS LI-RADS (January 2018 to August 2021). CEUS was performed within 4 weeks of CT or MRI. Tissue histologic and CT or MRI follow-up data were used as reference standards. Clinical effect of CEUS for HCC was evaluated in observations 10 mm or larger categorized as CT/MRI LR-4 and LR-M. Results Included were 109 participants (mean age, 64.3 years ± 8.3 [SD]; 68.8% [75 of 109] male participants) with 113 observations (≥10 mm) categorized as CT/MRI LR-4 (53.1%; 60 of 113) or LR-M (46.9%; 53 of 113). CEUS resulted in management recommendation changes in 33.6% (95% CI: 25, 43; 38 of 113) of observations; among these, 95% (95% CI: 82, 99; 36 of 38) were correct. A total of 30.1% (34 of 113) of CT/MRI LR-4 and LR-M observations were categorized at CEUS as LI-RADS category LR-5 (definite HCC), making biopsy unnecessary; 94% (32 of 34) of these categorizations were correct. Of CT/MRI LR-4 observations, 7% (four of 60) were categorized as CEUS LR-M; subsequent biopsy confirmed non-HCC malignancy in all participants. Clinical impact of CEUS was more substantial for observations 20 mm or larger ( = 68); CEUS helped appropriately categorize both LR-5 and LR-M lesions as HCC and non-HCC malignancies, respectively, and resulted in management recommendation changes in 40% (27 of 68) of observations with 100% accuracy. Conclusion CEUS resolved some high-risk indeterminate liver observations (categorized as LR-4 and LR-M at CT or MRI), with particularly high clinical impact for observations measuring at least 20 mm. Clinical trial registration no. NCT03318380 © RSNA, 2025

Keywords:

References: Singal AG , Kanwal F , Llovet JM . Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy . Nat Rev Clin Oncol 2023. ; 20 ( 12 ): 864 – 884 .
Asafo-Agyei KO , Samant H . Hepatocellular Carcinoma . Treasure Island, FL: : StatPearls; , 2023. .
Chernyak V , Fowler KJ , Do RKG , et al. . LI-RADS: looking back, looking forward . Radiology 2023. ; 307 ( 1 ): e222801 .
Chernyak V , Fowler KJ , Kamaya A , et al. . Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients . Radiology 2018. ; 289 ( 3 ): 816 – 830 .
Marrero JA , Kulik LM , Sirlin CB , et al. . Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases . Hepatology 2018. ; 68 ( 2 ): 723 – 750 .
European Association for the Study of the Liver . EASL clinical practice guidelines: management of hepatocellular carcinoma . J Hepatol 2018. ; 69 ( 1 ): 182 – 236 . [Published correction appears in J Hepatol 2019;70(4):817.]
Omata M , Cheng AL , Kokudo N , et al. . Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update . Hepatol Int 2017. ; 11 ( 4 ): 317 – 370 .
Burak KW , Sherman M . Hepatocellular carcinoma: consensus, controversies and future directions. A report from the Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting . Can J Gastroenterol Hepatol 2015. ; 29 ( 4 ): 178 – 184 .
Lee JM , Park JW , Choi BI . 2014 KLCSG-NCC Korea practice guidelines for the management of hepatocellular carcinoma: HCC diagnostic algorithm . Dig Dis 2014. ; 32 ( 6 ): 764 – 777 .
Kudo M , Matsui O , Izumi N , et al. ; Liver Cancer Study Group of Japan . JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the Liver Cancer Study Group of Japan . Liver Cancer 2014. ; 3 ( 3–4 ): 458 – 468 .
Singal AG , Llovet JM , Yarchoan M , et al. . AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma . Hepatology 2023. ; 78 ( 6 ): 1922 – 1965 .
Wilson SR , Lyshchik A , Piscaglia F , et al. . CEUS LI-RADS: algorithm, implementation, and key differences from CT/MRI . Abdom Radiol (NY) 2018. ; 43 ( 1 ): 127 – 142 .
Lyshchik A , Kono Y , Dietrich CF , et al. . Contrast-enhanced ultrasound of the liver: technical and lexicon recommendations from the ACR CEUS LI-RADS working group . Abdom Radiol (NY) 2018. ; 43 ( 4 ): 861 – 879 .
Jang HJ , Kim TK , Burns PN , Wilson SR Sr . CEUS: An essential component in a multimodality approach to small nodules in patients at high-risk for hepatocellular carcinoma . Eur J Radiol 2015. ; 84 ( 9 ): 1623 – 1635 .
Chiorean L , Tana C , Braden B , et al. . Advantages and limitations of focal liver lesion assessment with ultrasound contrast agents: comments on the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) Guidelines . Med Princ Pract 2016. ; 25 ( 5 ): 399 – 407 .
Lyshchik A , Wessner CE , Bradigan K , et al. ; CEUS LI-RADS Trial Group . Contrast-enhanced ultrasound liver imaging reporting and data system: clinical validation in a prospective multinational study in North America and Europe . Hepatology 2024. ; 79 ( 2 ): 380 – 391 .
Kono Y , Piscaglia F , Wilson SR , et al. ; CEUS LI-RADS Trial Group . Clinical impact of CEUS on non-characterizable observations and observations with intermediate probability of malignancy on CT/MRI in patients at risk for HCC . Abdom Radiol (NY) 2024. ; 49 ( 8 ): 2639 – 2649 .
Li L , Mao S , Wang J , et al. . Intraindividual comparison of contrast-enhanced ultrasound using perfluorobutane with modified criteria versus CT/MRI LI-RADS Version 2018 for Diagnosing HCC in high-risk patients . AJR Am J Roentgenol 2023. ; 220 ( 5 ): 682 – 691 .
Hu J , Burrowes DP , Caine BA , et al. . Nodules identified on surveillance ultrasound for HCC: CEUS or MRI as the initial test? J Ultrasound Med 2023. ; 42 ( 6 ): 1181 – 1190 .
Caraiani C , Boca B , Bura V , Sparchez Z , Dong Y , Dietrich C . CT/MRI LI-RADS v2018 vs. CEUS LI-RADS v2017-can things be put together? Biology (Basel) 2021. ; 10 ( 5 ): 412 .

Authors

• Annalisa Berzigotti |
• Kristen Bradigan |
• John R Eisenbrey |
• David T Fetzer |
• Flemming Forsberg |
• Aya Kamaya |
• Yuko Kono |
• Cristina Kuon Yeng Escalante |
• Andrej Lyshchik |
• Alexandra Medellin-Kowalewski |
• Fabio Piscaglia |
• Virginia Planz |
• Iuliana-Pompilia Radu |
• Shuchi K Rodgers |
• Paul S Sidhu |
• Tania Siu Xiao |
• Corinne E Wessner |
• Stephanie R Wilson |